COVID-19 Prevalence in HIV-infected Patients

University Hospital, Strasbourg, France500 enrolled

Overview

North-east area of France was hit in February 2020 by the new coronavirus disease, more severely than other French regions. Factors affecting the evolution of the disease and its severity have been quickly identified, among them figuring different kinds of immune deficiency. Even if nowadays HIV infection is usually well controlled by ARV drugs, those patients with uncontrolled viral load and/or low CD4 cell counts, remain at higher risk of severe COVID infection. In this context, the primary objective of our study is aimed at evaluating the prevalence of SARS-CoV-2 antibodies in a cohort of HIV-infected patients followed-up in an HIV-infection care center. Secondary objectives are: evaluating whether the antibodies are protective or not, the kinetic of these antibodies, and HIV associated factors with the presence of antibodies.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

HIV Infections

Interventions

Blood SampleOTHER

Blood Sample

Eligibility

Medical Language ↔ Plain English

Inclusion Criteria: * adults (\> 18 years) * HIV-infected patients * subjects with social insurance * subjects able to understand study purposes, and to give a written and informed consent Exclusion Criteria : * subjects unable to understand informations on the study, and to provide informed consent * subjects under guardianship or curatorship * subjects under judicial protection

Outcomes

Primary Outcomes

Seroprevalence of SARS-CoV-2

SARS-CoV-2 antibodies will be detected with a rapid test detecting IgG and IgM, at inclusion, and during a 6-month and a 12-month visit, in order to assess the prevalence of the virus in this population.

Time frame: From baseline to 12 months